|
1
|
Zhou F, Zhang Y, Sun J and Yang X:
Characteristics of a novel cell line ZJU-0430 established from
human gallbladder carcinoma. Cancer Cell Int. 19:1902019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramachandran A, Srivastava DN and
Madhusudhan KS: Gallbladder cancer revisited: The evolving role of
a radiologist. Br J Radiol. 94:202007262021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hickman L and Contreras C: Gallbladder
cancer: Diagnosis, surgical management, and adjuvant therapies.
Surg Clin North Am. 99:337–355. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brandi G, Venturi M, Pantaleo MA and
Ercolani G: Cholangiocarcinoma: Current opinion on clinical
practice diagnostic and therapeutic algorithms: A review of the
literature and a long-standing experience of a referral center.
Digestive Liver Dis. 48:231–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2015. CA Cancer J Clin.
65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goetze TO: Gallbladder carcinoma:
Prognostic factors and therapeutic options. World J Gastroenterol.
21:12211–12217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang W, Zhao B, Li Y, Qi D and Wang D:
Modification of the 8th American joint committee on cancer staging
system for gallbladder carcinoma to improve prognostic precision.
BMC Cancer. 20:11292020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sharma A, Sharma KL, Gupta A, Yadav A and
Kumar A: Gallbladder cancer epidemiology, pathogenesis and
molecular genetics: Recent update. World J Gastroenterol.
23:3978–3998. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sternby Eilard M, Lundgren L, Cahlin C,
Strandell A, Svanberg T and Sandström P: Surgical treatment for
gallbladder cancer-a systematic literature review. Scand J
Gastroenterol. 52:505–514. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Mo Q and Wang X: Oncological role
of HMGA2 (Review). Int J Oncol. 55:775–788. 2019.PubMed/NCBI
|
|
11
|
Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z and You
T: HMGA2 induces transcription factor Slug expression to promote
epithelial-to-mesenchymal transition and contributes to colon
cancer progression. Cancer Lett. 355:130–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lovnicki J, Gan Y, Feng T, Li Y, Xie N, Ho
CH, Lee AR, Chen X, Nappi L, Han B, et al: LIN28B promotes the
development of neuroendocrine prostate cancer. J Clin Invest.
130:5338–5348. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun J, Sun B, Sun R, Zhu D, Zhao X, Zhang
Y, Dong X, Che N, Li J, Liu F, et al: HMGA2 promotes vasculogenic
mimicry and tumor aggressiveness by upregulating Twist1 in gastric
carcinoma. Sci Rep. 7:22292017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fedele M, Palmieri D and Fusco A: HMGA2: A
pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol.
326:19–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang X, Wang J and Wu J: Emerging roles
for HMGA2 in colorectal cancer. Transl Oncol. 14:1008942021.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao X, Dai M, Li Q, Wang Z, Lu Y and Song
Z: HMGA2 regulates lung cancer proliferation and metastasis. Thorac
Cancer. 8:501–510. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hombach-Klonisch S, Kalantari F, Medapati
MR, Natarajan S, Krishnan SN, Kumar-Kanojia A, Thanasupawat T,
Begum F, Xu FY, Hatch GM, et al: HMGA2 as a functional antagonist
of PARP1 inhibitors in tumor cells. Mol Oncol. 13:153–170. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zou Q, Xiong L, Yang Z, Lv F, Yang L and
Miao X: Expression levels of HMGA2 and CD9 and its
clinicopathological significances in the benign and malignant
lesions of the gallbladder. World J Surg Oncol. 10:922012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding
J, Liang L, Hu J, Shen H, Chen Z, et al: MicroRNA-26a acts as a
tumor suppressor inhibiting gallbladder cancer cell proliferation
by directly targeting HMGA2. Int J Oncol. 44:2050–2058. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan L, Guo F, Wang L and Zou Q:
Prediction of tumor metastasis from sequencing data in the era of
genome sequencing. Brief Funct Genomics. 18:412–418. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scully OJ, Bay BH, Yip G and Yu Y: Breast
cancer metastasis. Cancer Genomics Proteomics. 9:311–320.
2012.PubMed/NCBI
|
|
22
|
Steeg PS: Targeting metastasis. Nat Rev
Cancer. 16:201–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Viallard C and Larrivée B: Tumor
angiogenesis and vascular normalization: Alternative therapeutic
targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun
W: Norcantharidin: A potential antiangiogenic agent for gallbladder
cancers in vitro and in vivo. Int J Oncol. 40:1501–1514.
2012.PubMed/NCBI
|
|
26
|
Li X, Hu Z, Shi H, Wang C, Lei J and Cheng
Y: Inhibition of VEGFA increases the sensitivity of ovarian cancer
cells to chemotherapy by suppressing VEGFA-mediated autophagy. Onco
Targets Ther. 13:8161–8171. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su L, Deng Z and Leng F: The mammalian
high mobility group protein AT-Hook 2 (HMGA2): Biochemical and
biophysical properties, and its association with adipogenesis. Int
J Mol Sci. 21:37102020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu J and Wei JJ: HMGA2 and high-grade
serous ovarian carcinoma. J Mol Med (Berl). 91:1155–1165. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chiou SH, Dorsch M, Kusch E, Naranjo S,
Kozak MM, Koong AC, Winslow MM and Grüner BM: Hmga2 is dispensable
for pancreatic cancer development, metastasis, and therapy
resistance. Sci Rep. 8:140082018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao W, Geng D, Li S, Chen Z and Sun M:
LncRNA HOTAIR influences cell growth, migration, invasion, and
apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer
Med. 7:842–855. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hao J, Yang Z, Wang L, Zhang Y, Shu Y,
Jiang L, Hu Y, Lv W, Dong P and Liu Y: Downregulation of BRD4
inhibits gallbladder cancer proliferation and metastasis and
induces apoptosis via PI3K/AKT pathway. Int J Oncol. 51:823–831.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shintani Y, Maeda M, Chaika N, Johnson KR
and Wheelock MJ: Collagen I promotes epithelial-to-mesenchymal
transition in lung cancer cells via transforming growth factor-beta
signaling. Am J Respir Cell Mol Biol. 38:95–104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ruan Y, Wang L and Lu Y: HDAC6 inhibitor,
ACY1215 suppress the proliferation and induce apoptosis of
gallbladder cancer cells and increased the chemotherapy effect of
gemcitabine and oxaliplatin. Drug Dev Res. 82:598–604. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Juríková M, Danihel Ľ, Polák Š and Varga
I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the
diagnosis of breast cancer. Acta Histochem. 118:544–552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nowakowska A and Tarasiuk J: Invasion and
metastasis of tumour cells resistant to chemotherapy. Postepy Hig
Med Dosw (Online). 71:380–397. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pittayapruek P, Meephansan J, Prapapan O,
Komine M and Ohtsuki M: Role of matrix metalloproteinases in
photoaging and photocarcinogenesis. Int J Mol Sci. 17:6682016.
View Article : Google Scholar
|
|
37
|
Zhou P, Wang C, Hu Z, Chen W, Qi W and Li
A: Genistein induces apoptosis of colon cancer cells by reversal of
epithelial-to-mesenchymal via a Notch1/NF-κB/slug/E-cadherin
pathway. BMC Cancer. 17:8132017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Simone V, Brunetti O, Lupo L, Testini M,
Maiorano E, Simone M, Longo V, Rolfo C, Peeters M, Scarpa A, et al:
Targeting angiogenesis in biliary tract cancers: An open option.
Int J Mol Sci. 18:4182017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun XN, Cao WG, Wang X, Wang Q, Gu BX,
Yang QC, Hu JB, Liu H and Zheng S: Prognostic impact of vascular
endothelial growth factor-A expression in resected gallbladder
carcinoma. Tumour Biol. 32:1183–1190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lertkiatmongkol P, Liao D, Mei H, Hu Y and
Newman PJ: Endothelial functions of platelet/endothelial cell
adhesion molecule-1 (CD31). Curr Opin Hematol. 23:253–259. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Freire Valls A, Knipper K, Giannakouri E,
Sarachaga V, Hinterkopf S, Wuehrl M, Shen Y, Radhakrishnan P, Klose
J, Ulrich A, et al: VEGFR1(+) metastasis-associated macrophages
contribute to metastatic angiogenesis and influence colorectal
cancer patient outcome. Clin Cancer Res. 25:5674–5685. 2019.
View Article : Google Scholar : PubMed/NCBI
|
